Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals manufactures specialty products and diagnostics
Based in MO
🤖
AI Overview
With $1.4M in lobbying spend across 18 quarterly filings, Mallinckrodt Pharmaceuticals is a significant lobbying presence.
$1.4M
Total Lobbying Spend
18
Quarterly Filings
1
Lobbying Firms Used
9
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $240K |
| 2019 | $240K |
| 2020 | $320K |
| 2021 | $320K |
| 2022 | $260K |
Lobbying Firms
TARPLIN, DOWNS & YOUNG, LLC
What They Lobby For
- prescription drug abuse and deterrence, non-interference PL 114-255 - 21st Century Cures, implementation Multi-modal analgesics S. 771 - Improving Access to Affordable Prescription Drugs Act S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry From Keeping Drugs Expensive Act of 2017 S. 469 - Affordable and Safe Prescription Drug Importation act H.R. 749 - Lower Drug Costs Through Competition Act H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017 S. 260/H.R. 849 - Protecting Seniors' Access to Medicare Act of 2017 H.R. 6 - SUPPORT for Patients and Communities Act S. 3120 - HEAL Substance Use Disorders Act S. 2680 - Opioid Crisis Response Act S. 2852 - Pandemic and All Hazards Preparedness Act
- H.R. 1- Tax Cuts and Jobs Act
- budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018
- prescription drug abuse and deterrence, non-interference PL 114-255 - 21st Century Cures, implementation Multi-modal analgesics S. 771 - Improving Access to Affordable Prescription Drugs Act S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry From Keeping Drugs Expensive Act of 2017 S. 469 - Affordable and Safe Prescription Drug Importation act H.R. 749 - Lower Drug Costs Through Competition Act H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017 S. 260/H.R. 849 - Protecting Seniors' Access to Medicare Act of 2017 H.R. 6 - SUPPORT for Patients and Communities Act S. 3120 - HEAL Substance Use Disorders Act S. 2680 - Opioid Crisis Response Act S. 2852 - Pandemic and All Hazards Preparedness Act S. 3282 - DEA Clearinghouse Act of 2018
- budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018 H.R. 6157 - HHS appropriations and continuing resolution
- budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018 H.R. 6157 - HHS appropriations and continuing resolution H.R. 695 - Department of Defense Appropriations Act
- Medicaid drug rebate program
- prescription drug abuse and deterrence, non-interference, opioids H.R. 269 - PAHPA Reauthorization of 2019 no specific bills, drug pricing and innovation
- budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations H.J.Res. 31 - Consolidated Appropriations Act, 2019
- debt ceiling, appropriations H.R. 2740 - HHS Appropriations, 2020 H.R. 3164 - FDA Appropriations, 2020 H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.